LRRK2 model

Test your novel Parkinson’s disease therapeutics aimed at targeting intracellular lysosomal pathways in the LRRK2 model

Parkinson’s disease (PD) is a neurodegenerative disorder that affects the motor systems in early stages, leading to symptoms such as trembling, slowing of movement, and muscle stiffness. The distinct disease mechanism can be modelled in different mouse models of PD. 

Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene, which encodes a kinase with a multitude of cellular functions (e.g., lysosomal function), are associated with PD. In line, the inhibition of LRRK2 is being increasingly pursued as a therapeutic strategy in PD treatment.

Apart from offering unique preclinical research services with demonstrated induced and genetic PD models, InnoSer offers fee-for-service LRRK2 mutant mouse models. Such models are highly relevant for studying novel gene therapeutics that target this protein.  

Take advantage of InnoSer’s expertise in modelling PD pathology, flexibility, and collaborative approach for your research. Our in-house neurology experts have long-standing experience with modelling LRRK2 pathology in vivo and are happy to help guide your decision on a study design fit for your current research goals.

LRRK2 model key model characteristics:

  • Transgenic mouse model with human LRRK2 with disease associated mutations (e.g., G2019S).
  • Combination of LRRK2 models with alpha-synuclein models (e.g., seeding).

Find the right model for you.

Compare our model capabilities and discover which of our neurology platforms suits your research needs

Belgian based preclinical neurology CRO mouse models

Key readouts

Test the efficacy of your treatments with the following biological readouts:

Related Parkinson’s Disease model options

MPTP Induced PD Models

InnoSer offers unique services using MPTP-based inducible PD models.

Transgenic Alpha-Synuclein Models

InnoSer offers fee-for-service transgenic α-syn mouse models.

GBA

Targeting intracellular lysosomal pathways using in vivo models with GBA-associated mutations. 

AAALAC Accreditation

InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.

AAALAC logo

Animal Welfare

The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why Innoser has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.

Need more information?

If you have any questions about how we can help accelerate your research,

then let us know